Neurocrine Biosciences Inc
(STU:NB3)
€
107.2
1.9 (1.8%)
Market Cap: 10.83 Bil
Enterprise Value: 10.11 Bil
PE Ratio: 35.07
PB Ratio: 4.67
GF Score: 88/100 Neurocrine Biosciences Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2020 / 04:35PM GMT
Release Date Price:
€92.54
(-1.28%)
Neena Marie Bitritto;Garg
Citigroup Inc., Research Division - VP & Analyst
All right. Are we live now?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
I believe we are live.
Neena Marie Bitritto;Garg
Citigroup Inc., Research Division - VP & Analyst
Okay. All right. Perfect. So hello, everyone. Thank you so much for joining the 15th Annual Citi Biopharma Conference. I'm Neena Bitritto-Garg, I'm one of the mid-cap biotech analysts here at Citi. So for our next fireside chat, I'm very excited to be joined by Kevin Gorman, CEO of Neurocrine Biosciences.
So before we jump into questions, Kevin, would you like to give some opening remarks?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Sure. Neena, thank you very much to you and Citibank for the opportunity to speak here. Our investors get to see me and you kind of in our natural environs as we are now, so all the clutter of my office.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot